GSK News Today: RSV Vaccine Demand Soars Amid Launch in Germany
In recent weeks, GSK has experienced a remarkable surge in demand for its RSV vaccine in Germany. This spike is linked to growing public concern over respiratory viruses and Germany’s proactive government immunization campaigns. As a result, GSK’s position in the pharmaceutical market has garnered significant attention from investors.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →